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OBJECTIVE: Echinophora platyloba DC is a widely used herbal medicine and food seasoning in Iran. It is claimed to
exert antimicrobial, antifungal, and antispasmodic effects. Despite the prevalent use of this plant as a food and
medicine, there are no reports on its possible toxic effects. To evaluate the safety of E. platyloba, we tested its acute
and sub-chronic toxicity in male and female Wistar rats.
METHODS: Rats were orally treated with four different single doses of E. platyloba total extract and screened for
signs of toxicity two weeks after administration. In the sub-chronic toxicity study, E. platyloba was administered for
45 days. Mortality, clinical signs, body weight changes, hematological and biochemical parameters, gross findings,
organ weights, and histological markers were monitored during the study.
RESULTS: We found no mortality and no abnormality in clinical signs, body weight, or necropsy findings in any of
the animals in the acute study. The results of the subchronic study showed no significant difference in
hematological parameters in either sex. There was a significant increase in lactate dehydrogenase in the female
groups. A significant increase in the relative lung weight of female rats was noted at 500 mg/kg. Histopathological
examinations revealed intra-alveolar hemorrhage in the male rats (500 mg/kg). In the females, congestion of the
alveolar capillaries (at 500 mg/kg) and liver bridging necrosis (at 200 mg/kg) were significantly increased.
CONCLUSION: The no observed adverse effect level of E. platyloba was determined to be 200 and 50 mg/kg for male
and female rats, respectively.
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INTRODUCTION
The Apiaceae family is of particular interest in food and
medicinal chemistry because it includes many commonly
consumed plants, such as celery, carrot, fennel, caraway,
and dill. Coumarins, polyacetylenes, flavonoids, sesquiter-
penes, and phthalides are among the important chemical
constituents of this family, along with biologically active
essential oils (1-5). Iran’s climate conditions are especially
suitable for the growth of apiaceous plants, as demonstrated
by the growth of 114 wild genera with 12 endemic genera
(6), most of which are consumed daily as food or used in
traditional medicine.
Echinophora is a ten-species genus of Apiaceae that contains
four species native to Iran, including E. orientalis, E. sibthor-
piana, E. cinerea, and E. platyloba (6). Called ‘‘Khousharizeh’’ or
‘‘Tigh Touragh’’ in Persian, E. platyloba is widely used in
western and central Iran as a food seasoning and edible
vegetable. Local people add the plant to pickles and tomato
pastes as an antifungal and antimicrobial preservative (7).
These effects have been demonstrated in several experiments.
For example, alcoholic extracts of E. platyloba inhibited Candida
albicans (7), Trichophyton spp., Microsporum (8), Pseudomonas,
and Staphylococcus growth, but it was not effective against
Aspergillus (9). Moreover, it could increase the effect of
amphotericin B against C. albicans (10). E. platyloba is also
traditionally used as an antispasmodic in dysmenorrhea, and
its efficacy was proven in a clinical trial (11). Moreover, its
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497hydroalcoholic extract and essential oil were shown to have
acceptable antispasmodic effects in the rat ileum (12).
Despite the widespread folk uses and pharmacological
effects of E. platyloba, there have been no toxicological
studies on its safety. Therefore, in this study, we investi-
gated the acute and repeated-dose (45 days) toxicity of E.
platyloba in Wistar rats.
MATERIALS AND METHODS
Plant material and hydroalcoholic extract
preparation
The aerial parts of the plant were collected from
Charmahal-Bakhtiary, Iran, in April 2009 and dried away
from direct sunlight. The plant was authenticated by M. K.,
and a voucher specimen (Registration Number 1030) was
deposited in the Herbarium of the School of Pharmacy
(Shaheed Beheshti University of Medical Sciences, Tehran,
Iran). The plant samples were ground to fine powder and
macerated with EtOH:H2O (80:20) three times. The extract
was concentrated to dryness first via eliminating EtOH in a
rotary evaporator and then removing the H2O by freeze
drying.
Evaluation of toxicity following a single-dose
administration
Four-week-old Wistar rats of both sexes were purchased
from Razi Research Institute (Hesarak, Karaj, Iran) and
acclimated to holding facilities for two weeks prior to
dosing. The animals were randomly assigned to control and
four treatment groups (five rats per sex per group) and
housed in clear plastic cages containing wood shavings for
bedding. Each cage contained five rats of the same sex fed
normal laboratory chow (Pars Co., Tehran, Iran) and tap
water ad libitum throughout the study. Environmental
conditions were maintained at 23¡2 ˚C and a relative
humidity of 40¡10% with a 12 h light/dark cycle. At the
onset of dosing, the males weighed 164¡19 g, and the
females weighed 142¡15 g. The research was conducted in
accordance with internationally accepted principles for
laboratory animal use and care (NIH Publication no. 85–
23, revised in 1985).
Administration
The animals were fasted for 4 h prior to dosing. The
extract was administered by gavage at doses of 50, 500,
1,000, and 2,000 mg/kg body weight. The control rats
received tap water by gavage in the same volume.
Observations
The rats were observed for clinical signs prior to dosing,
at 1, 2, 3, 4, 5, 6, 7, and 8 h post-dosing and daily thereafter
for 14 days. They were also monitored daily for mortality,
any changes in food and water consumption, and any
additional clinical or behavioral signs of toxicity. The
animal body weights were measured prior to dosing and
on days 7 and 14. The numbers of dead animals in each
group at the end of the study were expressed as a
Figure 1 - Changes in male (A) and female (B) rats body weight with duration of acute treatment. Each point represents mean¡SEM,
n=5.
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established using the Probit method (13). All of the animals
were sacrificed on day 15.
Evaluation of toxicity following subchronic
treatment
Group assignment and treatment
The animals were randomly caged in clear plastic cages
containing wood shavings for bedding. Dosing was initiated
when the rats were 8 weeks old, at which point the males
and females weighed 200¡19 g and 161¡10 g, respectively.
The animals were divided into four dose groups (five rats
per sex per group). The first group was given 1 ml normal
saline and used as a control. The second, third, and fourth
groups were given single doses of 50, 200, and 500 mg/kg of
E. platyloba by gavage daily. All of the solutions were
prepared just prior to dosing and were kept chilled and
tightly capped.
In vivo observations
Observations of mortality and toxicological signs were
made daily for 45 days. The onset, intensity, and duration of
these symptoms, if any, were recorded. The weight of each
rat was recorded on day 0 and at weekly intervals
throughout the course of the study. Food and water
consumption was measured three times per week.
Biochemical and hematology analysis
After 45 days, 12 h-fasted animals were anesthetized with
the IP injection of a mixture containing ketamine (40 mg/
kg) and xylazine (10 mg/kg). The jugular vein was exposed,
and blood samples were obtained by jugular vein puncture
(14). The following hematological parameters were deter-
mined with the Sysmex K-1000 fully automated hematology
analyzer: erythrocyte (RBC), total and differential leukocyte
(WBC), hematocrit (Hct), hemoglobin (Hb), platelet count,
mean corpuscular volume (MCV), mean corpuscular hemo-
globin (MCH), mean corpuscular hemoglobin concentration
(MCHC), mean platelet volume (MPV), platelet distribution
width (PDW), and red distribution width (RDW). Blood
samples for biochemical analyses were centrifuged at
3,0006g for 5 min, and the plasma was collected and
analyzed for glucose, uric acid, creatinine, albumin, choles-
terol, low-density lipoprotein (LDL), high-density lipopro-
tein (HDL), very low-density lipoprotein (VLDL),
triglycerides, aspartate aminotransferase (AST), alanine
aminotransferase (ALT), urea, total protein, and lactate
dehydrogenase (LDH) using a COBAS Mira S chemistry
analyzer (Roche Diagnostic Systems, West Sussex, England).
Necropsy
Following blood collection, the rats were sacrificed by
decapitation, and the organs identified in Table 3 were
removed, weighed, and examined macroscopically. The
Figure 2 - Changes in male (A) and female (B) rats body weight with duration of subchronic treatment. Each point represents
mean¡SEM, n=5.
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499organs were then preserved in 10% neutral buffered
formalin and prepared for microscopic histopathological
examinations.
Statistics
The mean¡SEM was calculated for body weights, food
consumption, organ/body weight ratios, and hematological
and biochemistry factors. The difference between dose groups
and controls was separately evaluated for males and females
with a one-way analysis of variance (ANOVA) followed by
Tukey’s test. p-values of 0.05 or less were considered to be
significant. Because no treatment-related animal deaths were
observed, the LD50 values were not measured.
RESULTS
Acute study
All of the rats treated with different concentrations of
total extracts of E. platyloba were alive for all 14 days of
observation. Normal body weight gains were observed in
the males and females of all of the dose groups. No
abnormal gross findings were observed in any of the
animals. The oral acute toxicity of E. platyloba total extract
(LD50) was therefore considered to be unclassified; doses
up to 2,000 g/kg did not induce death or toxic symptoms.
Subchronic study
There was no significant difference in body weights
between the control and treatment groups (Figures 1 and 2).
There was no significant difference between the food
consumption of E. platyloba-treated animals and controls.
No death was found in any of the groups throughout the
experimental period, and no abnormal gross findings were
observed in any of the animals. The results of the
hematological study are shown in Table 1. No treatment-
related changes in hematological parameters were observed
during the study period. Biochemical parameter evaluation
showed an increase in LDH levels in the 200 and 500 mg/kg
female groups (Table 2). No significant differences were
observed between the vehicle control and E. platyloba
treatment groups in the other biochemical parameters, such
as ALT, AST, creatinine, and/or urea. Organ weights
measured at necropsy showed increases in the relative lung
weights of the 500 mg/kg-treated female rats (Table 3).
Histopathological examinations showed intra-alveolar
hemorrhage in the male rats (500 mg/kg). In the female
rats, congestion of the alveolar capillaries (at 500 mg/kg)
and liver bridging necrosis (at 200 mg/kg) were signifi-
cantly increased compared with the control group. No
changes were observed in any of the other parameters
evaluated, including alveolar collapse, septal thickness,
interstitial infiltrate, intra-alveolar neutrophil counts, alveo-
lar edema, and fatty changes in the lung, hepatocyte
regeneration/degeneration, architectural distortion, necro-
sis, interface hepatitis, portal infiltration, and obstruction/
dilatation of the bile duct in the liver. No histological
findings in the kidney or heart could be attributed to the E.
platyloba treatment.
DISCUSSION
Complementary and alternative medicines (CAMs), such
as herbal remedies, require thorough safety and efficacy
Table 1 - Hematologic parameters in Wistar rats after 45 days treatment with E. platyloba.
Sex Group
WBC
(/ml)
RBC
(10
6/mm
3)
Hb
(g%)
HCT
(%)
Male Control 11200¡521 9.22¡0.1 16.4¡0.24 48.17¡0.46
50 9900¡1121.45 8.21¡0.3 16.01¡0.1 46.2¡0.45
200 9300.23¡645.23 8.28¡0.5 14.6¡0.09 44.4¡0.42
500 8700.65¡1117.89 7.66¡0.9 15.8¡0.6 44.7¡0.8
Female Control 7700.89¡189.49 7.46¡0.1 14.77¡0.1 39.1¡0.6
50 8700¡425.25 7.1¡0.07 14.36¡0.02 37.46¡0.2
200 7300¡202.45 7¡0.2 13.6¡0.1 36.45¡0.4
500 7700¡1128.06 7.5¡0.1 13.3¡0.07 36.4¡1.1
Sex Group
MCV
(fi)
MCH
(pg)
MCHC
(%)
MPV
(fi)
Male Control 53¡0.06 18¡03 4 . 3 ¡0.25 7.2¡0.25
50 52.6¡0.3 18¡0 35.25¡0.25 7.4¡0.23
200 58.62¡0.4 18¡0.05 34.75¡0.25 6.7¡0.18
500 50.66¡0.06 21.3¡2.5 35.75¡0.9 9.3¡0.89
Female Control 52.75¡0.06 20.3¡0.25 38.3¡0.25 6.7¡0.1
50 52.25¡0.45 20¡2.3 37.75¡0.05 6.66¡0.05
200 52¡0.8 21.41¡3.6 37¡0 6.65¡0.1
500 51.75¡0.9 18.1¡2.37 36.5¡1.1 6.5¡0.1
Sex Group
Platelets
(1000/ml)
RDW
(%)
PDW
(%)
Male Control 819.58¡142 13.3¡0.2 8.65¡1
50 841.98¡56.32 13.1¡0.08 8.4¡0.1
200 875.6¡69.22 13.1¡0.34 7.63¡0.2
500 800.36¡98.3 13.05¡0.3 7.6¡0.2
Female Control 935¡52 12.25¡0.21 7.62¡0.1
50 854.23¡25.4 12.1¡0.3 7.52¡0.2
200 921.89¡89.6 12¡0.31 7.4¡0.05
500 732.6¡124.3 11.9¡0.1 7.17¡0.2
Data presented as mean¡S.E.M. for N=5 .
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500evaluation due to their growing use all over the world (15).
Although many traditional herbal remedies are available
and some have been verified by clinical trials, their safety is
often still questioned by consumers.
E. platyloba DC is native to Iran and is used in traditional
medicine and consumed as a vegetable (7,16).
Despite preliminary evidence of its therapeutic benefits,
no toxicology studies have been performed on E. platyloba
extracts. In the present study, the acute and subchronic
toxicity of E. platyloba DC was evaluated in Wistar rats. The
oral LD50 value in this study suggests that E. platyloba DC is
a relatively nontoxic plant (17).
Generally, reductions in body weight gain and internal
organ weights are considered to be simple and sensitive
indices of toxicity after exposure to toxic substances (18).
Oral gavage of E. platyloba at up to 500 mg/kg in male and
female Wistar rats was not associated with any mortality or
abnormality in their general condition, behavior, growth,
food and water consumption, or body weight. Additionally,
treatment with E. platyloba extract did not produce
any statistically significant difference in hematological
parameters. The observed elevation in LDH, an initial
indicator of myopathy, in females indicates the potential for
muscular damage. LDH levels can be diagnostic of
myocardial or skeletal muscle injuries (14), but there were
no treatment-related heart histopathological findings. Thus,
the potential effects of E. platyloba treatment on cardiac
muscle should be investigated further.
A significant increase in relative lung weight was also
observed. This phenotype may have been caused by the
congestion of the alveolar capillaries by retaining blood in the
lung. Moreover, the intra-alveolar hemorrhage observed in
the male rats (500 mg/kg) indicates that E. platyloba DC may
have some effects on this organ. The liver bridging necrosis
observed in female rats (200 mg/kg) was not dose–dependent
and therefore was not considered to be a treatment-related
effect. Additionally, no indicators of liver injury, such as ALT
and AST, were observed.
Based on the results of this study, the no observed
adverse effect level (NOAEL) of total E. platyloba extract was
Table 2 - Biochemical parameters of Wistar rats after 45 days treatment with E.platyloba.
Sex Dose mg/kg
blood sugar
(mg/dl) Creatinine (mg/dl) Uric Acid (mg/dl)
Triglycerides
(mg/dl)
Male Control 162¡10.19 0.42¡0.02 2.96¡0.9 55.2¡7.13
50 202.6¡23.02 0.42¡0.04 2.5¡0.54 48¡7.34
200 219.65¡23.75 0.54¡0.05 3.92¡0.73 68.8¡6.7
500 379.5¡4.05 0.57¡0.09 2.97¡0.35 72.8¡17.6
Female Control 291.3¡28.34 0.5¡0.05 5¡0.65 82.2¡15. 5
50 151.4¡11.9* 0.44¡0.05 4.14¡0.84 66.6¡11.25
200 148.2¡2.7* 0.5¡0.0 3.78¡0.0.51 52¡8.24
500 177.6¡23.64 0.46¡0.06 3.08¡0.99 62¡6.1
Sex Dose mg/kg
Cholesterol
(mg/dl)
HDL
(mg/dl)
LDL
(mg/dl)
VLDL
(mg/dl)
Male Control 72¡7.17 38.4¡4.67 22.4¡3.3 11.2¡1.3
50 84.2¡4.93 48.4¡7.6 26.2¡6.5 9.6¡7.4
200 76.4¡4.26 34.6¡4.2 27.4¡5.7 14.4¡1.63
500 92.25¡4.75 43¡6.67 36.25¡7.6 13¡0.7
Female Control 112.4¡9.6 69.5¡6.7 21.5¡3.8 16.6¡1.69
50 91¡3.8 91¡3.8 34.6¡5.6 13.2¡2.1
200 88.6¡6.67 89.2¡6.4 28¡7.7 10.4¡1.72
500 98.2¡7.37 92¡5.14 33.8¡6.2 12.4¡1.28
Sex Dose mg/kg
Urea
(g %)
SGOT
(IU/L)
SGPT
(IU/L)
LDH
(U/L)
Male Control 41.6¡1.91 130.8¡16.25 48¡4.84 942.8¡138.7
50 45¡4.48 144¡19.45 58¡6.39 1293¡189.13
200 50¡3.59 170.4¡16.7 61.25¡10.2 2036.6¡117.98*
500 52.5¡1.65 191¡15.02 71.25¡7.2 2043¡122.88*
Female Control 60¡6.15 184.2¡26.02 66.8¡9.84 2126¡137.12
50 57.8¡6.03 206.2¡20.63 71¡9.18 1992.4 ¡243.18
200 46.6¡3.57 122.8¡5.21 41¡1.5 1743.3¡37.6
500 56.4¡4.83 126.8¡14.51 52.4¡2 1555.25¡86.96
Sex Dose mg/kg
Albumin
(gr/dl)
Total Protein
(mg/dl)
Male Control 3.98¡0.15 9.12¡0.56
50 3.59¡0.1 8.97¡0.39
200 3.25¡0.16 8.56¡0.48
500 3.73¡0.19 8.75¡0.72
Female Control 3.32¡0.26 7.86¡0.6
50 2.84¡0.17 7.69¡0.52
200 3.13¡0.33 8.14¡0.69
500 3.76¡0.18 7.39¡0.49
Data presented as mean¡S.E.M. for N= 5. Significantly different from control: *p , 0.05.
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female rats, respectively. This result indicates that gender is
one factor that could influence the response to E. platyloba,
and females are more sensitive than males to its subchronic
toxicity.
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